UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
January 10, 2011
Date of Report (Date of earliest event reported)
NPS PHARMACEUTICALS, INC. |
| (Exact name of registrant as specified in its charter) |
Delaware | 0-23272 | 87-0439579 |
(State or other jurisdiction of
incorporation) | (Commission File Number) | (I.R.S. Employer
Identification Number) |
550 Hills Drive, 3rd Floor
Bedminster, NJ 07921
(Address of principal executive offices)
(908) 450-5300
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
⃞ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
⃞ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
⃞ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
⃞ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
On January 10, 2011, NPS Pharmaceuticals, Inc. (the “Company”) issued a press release announcing the completion of the 24-week treatment phase of the Company’s Phase 3 registration study of GATTEX® (teduglutide) known as STEPS.
A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
ITEM 9.01. | Financial Statements and Exhibits. |
(d) Exhibits
Exhibit No. | Description |
| 99.1 | Press Release of NPS Pharmaceuticals, Inc. dated January 10, 2011. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: | January 10, 2011 | NPS PHARMACEUTICALS, INC. |
| | |
| | By: | /s/ EDWARD STRATEMEIER |
| | | Edward Stratemeier |
| | | Senior Vice President, General Counsel and |
| | | Secretary |
EXHIBIT INDEX
Exhibit No. | Description |
| 99.1 | Press Release of NPS Pharmaceuticals, Inc. dated January 10, 2011. |
